drugset / Trial / NCT01770145

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145

Phase 4 Completed 127 enrolled Supernus Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.

Timeline

Start
2012-12
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Apomorphine Unknown Subcutaneous
Background Levodopa Small molecule
Background Trimethobenzamide Small molecule 300 mg Oral